CAT-2003: Phase I started

Catabasis began a 2-part, double-blind, placebo-controlled, U.S. Phase I trial of CAT-2003 in about 84 subjects. The first part will evaluate single ascending-doses of 1,000 and 2,000 mg CAT-2003 in h...